AU2005318190B2 - Cladribine regimen for treating multiple sclerosis - Google Patents

Cladribine regimen for treating multiple sclerosis Download PDF

Info

Publication number
AU2005318190B2
AU2005318190B2 AU2005318190A AU2005318190A AU2005318190B2 AU 2005318190 B2 AU2005318190 B2 AU 2005318190B2 AU 2005318190 A AU2005318190 A AU 2005318190A AU 2005318190 A AU2005318190 A AU 2005318190A AU 2005318190 B2 AU2005318190 B2 AU 2005318190B2
Authority
AU
Australia
Prior art keywords
cladribine
months
period
administered
reached
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2005318190A
Other languages
English (en)
Other versions
AU2005318190A1 (en
Inventor
Giampiero De Luca
Maria Lopez-Bresnahan
Alain Munafo
Arnaud Ythier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Merck Serono SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36227798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2005318190(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Serono SA filed Critical Merck Serono SA
Publication of AU2005318190A1 publication Critical patent/AU2005318190A1/en
Assigned to MERCK SERONO SA reassignment MERCK SERONO SA Alteration of Name(s) of Applicant(s) under S113 Assignors: LABORATOIRES SERONO S.A.
Application granted granted Critical
Publication of AU2005318190B2 publication Critical patent/AU2005318190B2/en
Priority to AU2011200768A priority Critical patent/AU2011200768B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2005318190A 2004-12-22 2005-12-20 Cladribine regimen for treating multiple sclerosis Expired AU2005318190B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2011200768A AU2011200768B2 (en) 2004-12-22 2011-02-23 Cladribine regimen for treating multiple sclerosis

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US63866904P 2004-12-22 2004-12-22
EP04106909 2004-12-22
EP04106909.7 2004-12-22
US60/638,669 2004-12-22
PCT/EP2005/056954 WO2006067141A1 (en) 2004-12-22 2005-12-20 Cladribine regimen for treating multiple sclerosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2011200768A Division AU2011200768B2 (en) 2004-12-22 2011-02-23 Cladribine regimen for treating multiple sclerosis

Publications (2)

Publication Number Publication Date
AU2005318190A1 AU2005318190A1 (en) 2006-06-29
AU2005318190B2 true AU2005318190B2 (en) 2010-11-25

Family

ID=36227798

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2005318190A Expired AU2005318190B2 (en) 2004-12-22 2005-12-20 Cladribine regimen for treating multiple sclerosis
AU2011200768A Expired AU2011200768B2 (en) 2004-12-22 2011-02-23 Cladribine regimen for treating multiple sclerosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2011200768A Expired AU2011200768B2 (en) 2004-12-22 2011-02-23 Cladribine regimen for treating multiple sclerosis

Country Status (25)

Country Link
US (2) US7713947B2 (enExample)
EP (7) EP3332789B1 (enExample)
JP (7) JP5795456B2 (enExample)
KR (1) KR20070091662A (enExample)
AR (1) AR052830A1 (enExample)
AU (2) AU2005318190B2 (enExample)
BR (1) BRPI0517132B8 (enExample)
CA (2) CA2588966C (enExample)
CY (3) CY1112614T1 (enExample)
DK (3) DK3332789T3 (enExample)
EA (1) EA015799B1 (enExample)
ES (2) ES2921858T3 (enExample)
FI (1) FI4070800T3 (enExample)
FR (1) FR18C1008I2 (enExample)
HR (1) HRP20120228T1 (enExample)
HU (3) HUE070333T2 (enExample)
IL (2) IL183930A0 (enExample)
LT (3) LT4070800T (enExample)
LU (1) LUC00064I2 (enExample)
MX (1) MX2007007610A (enExample)
NO (1) NO20073813L (enExample)
PL (4) PL2805723T3 (enExample)
SG (1) SG160391A1 (enExample)
SI (3) SI2805723T1 (enExample)
WO (1) WO2006067141A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0517132B8 (pt) 2004-12-22 2021-05-25 Laboratoires Serono S A uso de cladribina para preparação de uma formulação farmacêutica para tratamento de esclerose múltipla
CA2649810A1 (en) * 2006-05-24 2007-11-29 Laboratoires Serono S.A. Cladribine regimen for treating multiple sclerosis
EP2343074A1 (en) 2009-12-23 2011-07-13 Merck Serono S.A. Use of purine analogues for treating airway diseases
WO2011117267A1 (en) 2010-03-24 2011-09-29 Merck Serono Sa Cladribine treatment of multiple sclerosis in patient groups defined by genotype
EP2428201A1 (en) 2010-09-08 2012-03-14 Merck Serono S.A. Oral administration of nucleoside monophosphates
WO2012097867A1 (en) 2011-01-18 2012-07-26 Synthon Bv Cladribine particles and pharmaceutical compositions comprising them
GB201401465D0 (en) 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
GB2564717A (en) 2017-07-21 2019-01-23 Chord Therapeutics S A R L Use of cladribine for treating autoimmune neuromuscular disease
CN119097635A (zh) * 2017-11-24 2024-12-10 默克专利股份公司 用于治疗进展型形式的多发性硬化症的克拉屈滨疗法
US20240226284A1 (en) 2020-09-10 2024-07-11 Merck Patent Gmbh Novel treatment regimen for the treatment of autoimmune disorders
GB2601786A (en) * 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087101A2 (en) * 2003-03-28 2004-10-14 Ivax Corporation Oral formulations of cladribine

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (en) 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US4964848A (en) * 1988-06-27 1990-10-23 Bloom Philip M Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
US5641757A (en) 1994-12-21 1997-06-24 Ortho Pharmaceutical Corporation Stable 2-chloro-2'-deoxyadenosine formulations
JPH10512549A (ja) 1994-12-22 1998-12-02 オーソ・フアーマシユーチカル・コーポレーシヨン 可溶性の２−クロロ−２’−デオキシアデノシン配合物
US6194395B1 (en) 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
WO2000064918A1 (en) 1999-04-28 2000-11-02 Sterrenbeld Biotechnologie North America, Inc. METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE
DE10237146A1 (de) * 2002-08-13 2004-03-04 Medac Gesellschaft für klinische Spezialpräparate mbH Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose
EP1556400B1 (en) 2002-09-25 2013-05-01 Brigham Young University Method for the preparation of 2-halo-2 -deoxyadenosine compounds from 2 -deoxyguanosine
GB2394658A (en) * 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
EP1596873A1 (en) * 2003-02-25 2005-11-23 Applied Research Systems ARS Holding N.V. Combined use of ribavirin and interferon beta in demyelinating diseases
ES2584183T3 (es) 2003-03-28 2016-09-26 Ares Trading S.A. Formulaciones de cladribina para suministro mejorado oral y transmucosa
BRPI0517132B8 (pt) 2004-12-22 2021-05-25 Laboratoires Serono S A uso de cladribina para preparação de uma formulação farmacêutica para tratamento de esclerose múltipla
CA2649810A1 (en) * 2006-05-24 2007-11-29 Laboratoires Serono S.A. Cladribine regimen for treating multiple sclerosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087101A2 (en) * 2003-03-28 2004-10-14 Ivax Corporation Oral formulations of cladribine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Grieb Pawel et al. Archivum Immunologiae Et Therapiae Experimentalis (1995) vol. 43, no. 5-6, pages 323-327 *
Stelmasiak et al. Medical Science Monitor (1998) vol. 4, no. 1, pages 4-8 *

Also Published As

Publication number Publication date
LTPA2018503I1 (lt) 2018-03-12
JP6092945B2 (ja) 2017-03-08
CA3087419C (en) 2023-03-07
CY1119790T1 (el) 2018-06-27
EP4070800B1 (en) 2024-10-16
CY2018006I1 (el) 2018-06-27
EP4070800A1 (en) 2022-10-12
US7713947B2 (en) 2010-05-11
NO20073813L (no) 2007-09-21
DK2805723T3 (da) 2018-01-29
LT4070800T (lt) 2025-01-10
EP2805723B1 (en) 2018-01-17
JP5795456B2 (ja) 2015-10-14
JP5908863B2 (ja) 2016-04-26
US8377903B2 (en) 2013-02-19
EP1827461A1 (en) 2007-09-05
ES3007339T3 (en) 2025-03-19
FR18C1008I2 (fr) 2019-03-01
CA2588966C (en) 2020-07-21
AU2011200768A1 (en) 2011-03-17
EP1827461B1 (en) 2012-02-29
JP2015180685A (ja) 2015-10-15
LUC00064I1 (enExample) 2018-02-14
CA3087419A1 (en) 2006-06-29
AR052830A1 (es) 2007-04-04
EP2275110A2 (en) 2011-01-19
JP2020193206A (ja) 2020-12-03
PL1827461T3 (pl) 2012-07-31
EP3332789B1 (en) 2022-04-06
EP2263678A2 (en) 2010-12-22
MX2007007610A (es) 2007-08-03
HUE070333T2 (hu) 2025-05-28
LUC00064I2 (enExample) 2018-03-28
CA2588966A1 (en) 2006-06-29
AU2011200768B2 (en) 2012-09-13
AU2005318190A1 (en) 2006-06-29
BRPI0517132A (pt) 2008-09-30
US20100203017A1 (en) 2010-08-12
IL212421A (en) 2014-01-30
EA200701221A1 (ru) 2008-02-28
SI2805723T1 (en) 2018-02-28
LTC2805723I2 (lt) 2022-04-25
FR18C1008I1 (enExample) 2018-03-30
FI4070800T3 (fi) 2025-01-14
PL4070800T3 (pl) 2025-03-10
EP2275110A3 (en) 2011-04-27
EP4523753A3 (en) 2025-05-28
JP2017101061A (ja) 2017-06-08
EP4523753A2 (en) 2025-03-19
JP6290962B2 (ja) 2018-03-07
JP2008524313A (ja) 2008-07-10
EP2263678A3 (en) 2011-04-27
EA015799B1 (ru) 2011-12-30
JP2013216664A (ja) 2013-10-24
PL3332789T3 (pl) 2022-08-22
KR20070091662A (ko) 2007-09-11
CY1112614T1 (el) 2016-02-10
BRPI0517132B8 (pt) 2021-05-25
SG160391A1 (en) 2010-04-29
HUS1800009I1 (hu) 2018-05-02
ES2921858T3 (es) 2022-09-01
EP2275110B1 (en) 2013-07-10
BRPI0517132B1 (pt) 2020-02-18
WO2006067141A1 (en) 2006-06-29
JP6430554B2 (ja) 2018-11-28
IL212421A0 (en) 2011-06-30
SI3332789T1 (sl) 2022-08-31
LT3332789T (lt) 2022-07-25
CY2018006I2 (el) 2018-06-27
EP3332789A1 (en) 2018-06-13
JP2016138128A (ja) 2016-08-04
JP2018165271A (ja) 2018-10-25
IL183930A0 (en) 2007-10-31
PL2805723T3 (pl) 2018-04-30
SI4070800T1 (sl) 2025-03-31
EP2805723A1 (en) 2014-11-26
HRP20120228T1 (hr) 2012-04-30
HUE059133T2 (hu) 2022-10-28
EP2263678B1 (en) 2014-06-11
US20090081163A1 (en) 2009-03-26
DK3332789T3 (da) 2022-07-11
DK4070800T3 (da) 2025-01-02

Similar Documents

Publication Publication Date Title
AU2011200768B2 (en) Cladribine regimen for treating multiple sclerosis
HK40083827A (en) Cladribine regimen for treating multiple sclerosis
HK40083827B (en) Cladribine regimen for treating multiple sclerosis
ES2382554T3 (es) Pauta posológica de cladribina para el tratamiento de la esclerosis múltiple
CN101090726A (zh) 治疗多发性硬化的克拉屈滨方案
HK1110517A (en) Cladribine regimen for treating multiple sclerosis

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: ADD THE CO-INVENTORS MUNAFO, ALAIN; YTHIER, ARNAUD AND LOPEZ- BRESNAHAN, MARIA

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired